Trekrezan for Health & Longevity
Evidence Review created on 10/25/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Trecrezan, Trecresan, Trekresan, Crezacin, Cresacin, Krezacin, Krezatsin, oxyethylammonium methylphenoxyacetate, hydroxyethylammonium methylphenoxyacetate, tris(2-hydroxyethyl)ammonium 2-methylphenoxyacetate, triethanolammonium o-cresoxyacetate, Immunotrezan, Trekrezolid, Trekresil, Trekvert, Trekvion, Trivisan-SZ
Motivation
Trekrezan (also spelled trecrezan; known in farming as crezacin) is a synthetic compound sold in Russia as an over-the-counter medicine for resistance to environmental stress and seasonal colds. Chemically it is a simple salt that joins a common industrial base with a small acid related to plant growth regulators. Its makers describe it as a body-wide “resistance booster” that prompts the immune system to release its own antiviral signals.
The compound came out of a Soviet chemistry institute in Siberia in the 1970s, first as a crop and livestock growth stimulant and later as a human medicine. It belongs to a Russian tradition of drugs meant to raise general resilience rather than treat one disease, a tradition that has drawn interest from people pursuing healthy aging. Almost all research on it is in Russian and comes from a small circle of laboratories.
This review examines what the human, animal and laboratory evidence shows about Trekrezan’s benefits and risks, how it is used, and how far that evidence reaches toward long-term health and longevity.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists narrative reviews that discuss Trekrezan’s pharmacology, toxicology and clinical use in depth.
-
Pharmacology of trekrezan, a new immune modulator and adaptogenic - Shabanov et al., 2014
Open-access Russian review from the Military Medical Academy group behind most human performance studies; covers toxicity, interferon induction and combination use with polyoxidonium, an immunomodulator (immune-adjusting drug), in rat inflammation models.
-
Contribution of the Scientific School of Academician M.G. Voronkov to the Development of the Chemistry of Biologically Active Atranes (Protatranes and Hydrometallatranes) (A Review) - Kondratenko & Kochina, 2021
English chemistry-and-biology history of Trekrezan and its analogues, written from within the developer’s research lineage; explains the salt’s structure, rodent toxicity values and the claimed range of actions.
-
Efficacy and safety of Trecresan. Immunomodulator with adaptogenic properties - Maksimov & Alyautdin, 2017
Secondary summary of Russian clinical reports (tuberculosis, alcohol withdrawal, heart failure, cold exposure); the only accessible source for several human study details, though it adds no original data.
Only three items are listed: the literature on Trekrezan is small, almost entirely in Russian, and most of it is primary laboratory work or paywalled. None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Trekrezan; web and on-site searches returned nothing, consistent with the compound being a Russian-registered medicine outside these platforms’ coverage.
Grokipedia
No Grokipedia article on Trekrezan exists.
Examine
No Examine article on Trekrezan exists. Examine.com does not typically cover medicines registered only in Russia.
ConsumerLab
No ConsumerLab article on Trekrezan exists. ConsumerLab does not typically cover medicines registered only in Russia.
Systematic Reviews
No systematic reviews or meta-analyses for Trekrezan were found on PubMed as of October 25, 2026.
Mechanism of Action
Trekrezan is the salt tris(2-hydroxyethyl)ammonium 2-methylphenoxyacetate: a triethanolamine cation (an industrial base) paired with the anion of 2-methylphenoxyacetic acid, a relative of synthetic plant growth regulators. According to a review from the developer’s research school, its creators call such salts protatranes and attribute the activity to the combination of both parts (Kondratenko 2021). The developer’s institute and collaborators, who have a direct interest in its adoption, produced nearly all data below.
- Immune signaling: in vitro it stimulated proliferation of human blood immune cells through direct action on B lymphocytes (antibody-producing white cells) and raised lymphokine and monokine output (immune signaling proteins) (Shirinskiĭ 1993). The label adds induction of α- and γ-interferons (antiviral signaling proteins) and macrophage (scavenger-cell) activity (Vidal label).
- Protein synthesis: in experimental work it raised messenger RNA (the gene copy used to build a protein) for tryptophanyl-tRNA synthetase (an enzyme attaching tryptophan to transfer RNA, or tRNA, for protein building) (Nurbekov 2011).
- Oxidative stress: it reduced lipid peroxidation (oxidative damage to fats) in rat liver (Korda 1998) and in human lipoproteins in vitro (Korda 1997).
Competing view: the Vidal label states the exact mechanism is not established. No cited study identifies a molecular target, so the effects may reflect nonspecific stress responses.
Pharmacology: the Vidal label reports high oral bioavailability, rapid liver metabolism, renal excretion mainly as glucuronides (compounds tagged with glucuronic acid for urinary removal) and no accumulation. Half-life, selectivity, tissue distribution and the enzymes involved, including any cytochrome P450 (drug-metabolizing liver enzymes), are not published.
Historical Context & Evolution
In the early 1970s, chemist Mikhail Voronkov at the Irkutsk Institute of Organic Chemistry noticed that converting biologically active acids into triethanolamine salts increased their activity and water solubility. According to a review of his research school, the first such salt, whose crystal structure was solved in 1981, became crezacin, a growth stimulant for crops and livestock (Kondratenko 2021).
During the 1980s and 1990s the compound was developed for people as Trekrezan. Long-term administration to rats and mice did not raise spontaneous tumor rates (Tsapenko 1986). Immunology groups in Novosibirsk reported effects on blood-cell formation and antibody production in mice (Sukhenko 2001), and Russia registered it as an adaptogen (a substance claimed to raise nonspecific resistance to physical, chemical and biological stress) (Vidal label).
It came to be considered for health optimization through this adaptogen concept, which Soviet pharmacology applied to ginseng and eleuthero and extended to synthetic drugs for soldiers and athletes. In the 2000s the Military Medical Academy in St. Petersburg tested it as a “meteoadaptogen” for cold in people (Zarubina 2008) and for low oxygen in rats (Zarubina 2008).
Opinion has shifted in two directions. The current over-the-counter label narrowed the indications from immunodeficiency, heavy-metal poisoning and alcohol withdrawal (RLS label 2014) to respiratory infections, heavy workloads and environmental stress (Vidal label), and a 2021 post-registration study (Frolova 2021) added comparative infection data. On the other side, no placebo-controlled randomized trial has been published, and no study has examined aging or lifespan.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the human data are single open-label or small controlled studies from individual groups, and no lifespan or healthspan study exists in any species.
Medium 🟩 🟩
Shorter Acute Respiratory Viral Infections
In an open-label post-registration study of 130 adult outpatients with mild-to-moderate acute respiratory viral infection (ARVI), 100 took the registration holder’s (Grotex) product plus symptomatic care and 30 took symptomatic care alone (Frolova 2021); funding is not stated in the accessible text. There was no placebo or blinding, and symptoms were self-scored. The proposed route is immune stimulation seen in human cells in vitro (Shirinskiĭ 1993). A prevention claim rests only on a conference report cited in an older label (RLS label 2014).
Magnitude: Symptoms resolved 2.2 days sooner than in the untreated control group (no 95% confidence interval, the range likely to contain the true effect, reported); temperature had normalized by day 3 in 39.2% versus 10.4% of patients.
Physical Work Capacity Under Cold Stress
In 75 healthy men aged 20–24 exposed to −10 °C for 40 minutes, a single 0.2 g dose before exposure kept physical-performance and metabolic measures near comfortable-temperature levels, whereas cold lowered them without the drug (Zarubina 2008). A later review adds that a placebo group fared like untreated controls but describes no randomization or blinding (Maksimov 2017). Endurance reports in soldiers and athletes in that review give no control details.
Magnitude: Physical-performance indices (the PWC170 cycle-ergometer test of work output at a heart rate of 170 beats per minute, and dynamometry, i.e., muscle-force measurement) stayed at comfortable-temperature levels with the drug but fell with cold in the control and placebo groups; the accessible reports give no between-group outcome figure.
Low 🟩
Mental Work Capacity ⚠️ Conflicted
The label lists high intellectual workloads as an indication (Vidal label). In the cold-exposure study, cold lowered cognitive performance (Zarubina 2008); a review claims the drug normalized it yet reports no significant change (Maksimov 2017). Net: the only controlled test shows no clear mental-performance benefit.
Magnitude: Direction unclear: mental performance showed no statistically significant change (no change larger than chance would explain) in the drug group during cold exposure; the reports give no between-group outcome figure.
Cardiac Function in Chronic Heart Failure
A clinical study in chronic heart failure examined lipid peroxidation (Sabadyshin 1998). A later review reports that 0.6 g daily for 20 days lowered peripheral vascular resistance (resistance to blood flow in small arteries) and improved electrocardiogram and quality-of-life measures, without design or control details (Maksimov 2017).
Magnitude: Not quantified in available studies. Only a secondary review without figures describes the clinical outcomes.
Recovery From Alcohol Withdrawal ⭕️ Not Central to Health & Longevity
Uncontrolled clinical reports summarized in a review describe less headache, weakness and anxiety in alcohol and opioid withdrawal at 0.6 g daily for 20 days (Maksimov 2017), also noted in a review (Kondratenko 2021). This bears on addiction-recovery symptoms, a former label indication.
Magnitude: Not quantified in available studies. Only uncontrolled clinical reports without figures exist.
Tolerance of Low Oxygen and Heat
Low oxygen and overheating are label indications (Vidal label). Human data are a 2014-label heat report (RLS label 2014) and soldier field reports in hot, mid-altitude conditions summarized in a review (Maksimov 2017), both without design details. Rats adapting to intermittent low oxygen showed enhanced metabolic adaptation (Zarubina 2008).
Magnitude: Not quantified in available studies. The human reports give no design details or figures, and the rat data are metabolic only.
Liver Protection and Regeneration
A review reports that 0.6 g daily for 20 days in infectious hepatitis shortened jaundice and normalized liver tests sooner than in controls, without design details (Maksimov 2017). In rats it accelerated liver regeneration (Rasulov 1993) and limited toxin-induced hepatitis (Korda 1998).
Magnitude: Jaundice lasted 5–6 days less and blood biochemistry normalized 4–6 days earlier than in controls (secondary review; no 95% confidence interval or group sizes reported).
Speculative 🟨
Immune and Blood-Cell Modulation
In mice with induced immunodeficiency and anemia, it corrected anemia and restored antibody responses (Sukhenko 2001). A review reports immune-cell counts in clinical series (Maksimov 2017), unvalidated markers without outcome data.
Cellular Energy Under Stress
In rats with lung inflammation it raised ATP (the cell’s energy carrier) and lowered lactate (an oxygen-shortage by-product) in lung tissue and lymphocytes (Zarubina 2006). Basis is animal data only.
Vascular Lipid Handling
In experimental work it activated aortic-wall acid lipase (a fat-digesting enzyme) (Voronkov 2011), reported as antisclerotic (against artery hardening) (Voronkov 2010). No human vascular outcome exists.
Lifespan or Healthspan Extension
No lifespan or healthspan study exists in any species. The longevity interest rests on the adaptogen concept and mechanistic claims only.
Benefit-Modifying Factors
- Genetic polymorphisms: none studied. Clearance by glucuronidation suggests that reduced-function UGT1A1 variants (UGT1A1 is a liver enzyme attaching glucuronic acid; low function causes Gilbert syndrome, a harmless inherited bilirubin rise) could raise exposure; inferred, not measured.
- Baseline biomarkers: in the infection study, faster normalization of white-cell count and ESR (erythrocyte sedimentation rate, an inflammation marker) occurred only with baseline leukocytosis (high white-cell count) above three times normal and ESR above 20 mm/h; the abstract omits this restriction (Frolova 2021).
- Sex: no sex-specific analysis exists; the cold-exposure trial enrolled only young men (Zarubina 2008).
- Pre-existing conditions: reported benefits come from people with acute infection, heart failure, tuberculosis or withdrawal states; whether healthy, well-conditioned adults gain anything outside acute stress is untested.
- Age: most studies enrolled adults aged 18–60, though a heart-failure trial included people over 65 (Sabadyshin 1998); the Vidal label states pharmacokinetics are unchanged in older adults, but no study reports efficacy separately for older adults.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no adverse event has been documented in trials from more than one independent research group; the human safety record consists of label statements and two small studies.
Medium 🟥 🟥
No risk reaches Medium: no controlled human study has recorded any adverse event at a measurable rate.
Low 🟥
Allergic and Hypersensitivity Reactions
The current label lists hypersensitivity reactions, including anaphylaxis (a severe whole-body allergic reaction) and angioedema (rapid deep tissue swelling) (Vidal label), without rates. A 100-patient open-label study recorded none (Frolova 2021), too few to detect rare events. Rodent toxicity summarized in a review is low (Kondratenko 2021).
Magnitude: Not quantified in available studies. The label gives no frequency and no study has a comparison group that recorded a case.
Speculative 🟨
Tumors From the Triethanolamine Component ⚠️ Conflicted
The salt’s triethanolamine part caused tumors in mice by diet (Hoshino 1978) or skin (National Toxicology Program, NTP TR-518), not in rats (Maekawa 1986) or with crezacin (Tsapenko 1986). Net: unresolved, animal-only.
Kidney Strain at High Exposure
Rats drinking triethanolamine for two years developed accelerated chronic nephropathy (progressive kidney damage) (Maekawa 1986), at exposures far above medicinal use. Basis is animal data only.
Immune Overactivation in Autoimmune Disease
Immune-cell stimulation (Shirinskiĭ 1993) and claimed interferon induction could, in principle, aggravate autoimmune disease. Basis is mechanistic only; no human reports exist.
Risk-Modifying Factors
- Genetic polymorphisms: none studied; reduced-function UGT1A1 variants (Gilbert syndrome) could, by inference from glucuronide clearance, increase exposure to the drug and its triethanolamine component.
- Baseline biomarkers: no study links a baseline value to risk; the label’s diabetes caution (Vidal label) gives no glucose or HbA1c (long-term blood sugar) threshold.
- Sex: no sex-specific safety data exist; pregnancy and breastfeeding are label contraindications because no safety data exist (Vidal label).
- Pre-existing conditions: hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption (inherited inability to absorb these sugars) are contraindicated because each tablet contains 200 mg lactose (Vidal label); autoimmune disease or transplant immunosuppression carries an inferred risk.
- Age: the label reports unchanged pharmacokinetics in older adults and in liver or kidney impairment; a heart-failure trial included people over 65 (Sabadyshin 1998), but no study reports safety separately for older adults; children under 12 are excluded (Vidal label).
Key Interactions & Contraindications
Documented interactions:
- Other medicines: the label states that no undesirable interactions have been described (Vidal label), reflecting an absence of interaction studies rather than tested safety; symptomatic infection drugs co-used in an efficacy study caused no recorded adverse events, but interactions were not assessed (Frolova 2021).
Theoretical interactions (inferred from mechanism, not studied in humans):
- Immunosuppressants (drugs that dampen immune activity; e.g., cyclosporine, tacrolimus, prednisone, methotrexate): inferred from opposing immune stimulation; possible weaker disease or rejection control. Mitigation: prescriber review before combining.
- Interferons and interferon inducers (inducers being drugs that prompt the body to make interferons; e.g., peginterferon alfa, tilorone, Cycloferon, Kagocel): inferred from additive interferon induction; possible flu-like symptoms or excessive immune activation. Mitigation: non-overlapping courses.
- Drugs cleared by glucuronidation (acetaminophen/paracetamol, lamotrigine, valproate): inferred from a shared glucuronidation pathway; possible higher or lower levels of the co-administered drug, risking toxicity or loss of effect. Mitigation: drug-level checks for valproate or lamotrigine if combined.
- Adaptogen and immune-stimulating supplements (Eleutherococcus senticosus, Rhodiola rosea, Panax ginseng, Echinacea purpurea): inferred from additive stimulant-adaptogen and immunostimulant activity; unknown cumulative stimulation, including sleep disruption. Mitigation: no stacking during a course.
- Vaccination: inferred from enhanced antibody production in vaccinated mice (Voronkov 2004); possible altered vaccine response, direction untested in humans. Mitigation: no course in the days around a vaccination.
Populations who should avoid Trekrezan:
- Pregnancy and breastfeeding (label contraindication; no safety data) (Vidal label)
- Children under 12 years (label contraindication; no efficacy or safety data) (Vidal label)
- Hereditary lactose intolerance, lactase deficiency, or glucose-galactose malabsorption (label contraindication; lactose excipient) (Vidal label)
- Known hypersensitivity to any component (label contraindication) (Vidal label)
- Active autoimmune disease or organ-transplant immunosuppression (inferred from immune stimulation; no human data)
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Course-limited use: keeping to the label’s 8–14-day courses (Vidal label) limits cumulative exposure to the triethanolamine component, whose long-term effects in humans are unknown.
- Allergy vigilance: stopping at the first sign of urticaria (hives), lip or throat swelling, or breathing difficulty, and seeking emergency care for anaphylaxis, mitigates the label-listed hypersensitivity reactions.
- Infection red flags: the label calls for medical evaluation above 39 °C, above 38.5 °C for 3 days, above 37.5 °C for 2 weeks, or without improvement in 3 days (Vidal label); prevents delayed care of serious infection.
- Glucose checks in diabetes: daily home glucose readings during each course address the label’s unexplained caution in diabetes.
- Lactose screening: confirming lactose tolerance before use prevents intolerance symptoms from the 200 mg lactose excipient per tablet.
- Prescriber review with immune drugs: consulting the prescriber before combining with immunosuppressants or in autoimmune disease mitigates inferred immune overactivation or loss of disease control.
- Pharmaceutical product only: using registered tablets rather than agricultural crezacin avoids contaminants and unknown concentrations.
Therapeutic Protocol
Doses below are cited; other parameters without a citation (timing, cycling, titration steps) reflect common practice.
- Standard prevention course: 200 mg once daily after meals for 14 days, adults and children over 12 (Vidal label).
- Acute infection or high-workload course: 600 mg on day one (200 mg three times), then 200 mg daily for 7 days (Vidal label).
- Pre-exposure single dose: 0.2 g before cold exposure, the regimen tested by the Military Medical Academy group that popularized its “meteoadaptogen” use (Zarubina 2008).
- Extended research courses: 0.2–0.6 g daily for 20 days, and 200 mg three times daily for 90 days in tuberculosis care, as summarized in a review (Maksimov 2017); these exceed current label durations.
- Longevity use: no practitioner or clinic has published a continuous or healthy-aging protocol; per a review, the developer school around Mikhail Voronkov promoted it for stress adaptation (Kondratenko 2021).
- Time of day: after a meal per label (Vidal label); morning or midday by common practice, because no study has measured effects on sleep.
- Half-life: not published; the label describes rapid liver metabolism, kidney excretion as glucuronides and no accumulation (Vidal label).
- Single versus split dosing: a single daily dose for maintenance; the 600 mg first-day dose is split into three 200 mg doses (Vidal label).
- Genetic polymorphisms: no pharmacogenetic data exist; UGT1A1 reduced function (Gilbert syndrome) could, by inference, raise exposure and argues for standard rather than extended courses.
- Sex differences: none reported; the main performance trial enrolled only men, so responses in women are unmeasured.
- Age: most studies enrolled adults up to 60, though a heart-failure trial included people over 65 (Sabadyshin 1998); the Vidal label reports unchanged pharmacokinetics in older adults, so the same dose is used, with no age-specific efficacy data.
- Baseline biomarkers: laboratory improvements in infection were confined to patients with marked baseline inflammation (leukocytosis above three times normal and ESR above 20 mm/h), a restriction the abstract omits (Frolova 2021).
- Pre-existing conditions: diabetes calls for label caution; lactose intolerance and pregnancy exclude use (Vidal label); autoimmune disease warrants prescriber review.
Discontinuation & Cycling
- Short-term by design: the label defines 8- or 14-day courses, not lifelong use (Vidal label).
- Withdrawal effects: none reported; a review states that no dependence develops (Maksimov 2017).
- Tapering: not applicable; courses end abruptly at their final dose in all published regimens.
- Cycling: the 2014 label allowed repeat courses at intervals of 1–2 months (RLS label 2014); the current label is silent. No data show that cycling maintains efficacy.
- Stopping triggers: the label calls for seeing a doctor if an infection has not improved within 3 days and for reporting any worsening adverse reaction (Vidal label); stopping at a first allergy sign follows common practice.
Sourcing and Quality
- Registered medicine: sold over the counter in Russia as 200 mg tablets under several registrations, including Trekrezan (Grotex), Trekrezolid (Usolye-Sibirsky Chemical-Pharmaceutical Plant), Immunotrezan and Trekresil (Vidal label), and as a Grotex 20 mg/mL syrup (Vidal syrup label).
- What to look for: Russian registration number on the pack, an intact batch number and expiry date, storage at 2–25 °C (Vidal label) and a 2-year shelf life (RLS label 2014).
- Agricultural crezacin: the same molecule sold for crops and animals is not manufactured to pharmaceutical standards and is not a substitute.
- Excipients: each tablet contains 200 mg lactose monohydrate plus potato starch, sodium stearyl fumarate and colloidal silicon dioxide (Vidal label); the syrup is lactose-free, sweetened with maltitol and sucralose (Vidal syrup label).
- Third-party testing: no independent laboratory testing of any brand has been published; sourcing outside Russia relies on grey-market importers whose product identity is unverified.
Practical Considerations
- Time to effect: in patients with neurotic disorders taking 0.3 g daily alongside tranquilizers, a review describes effects from day 3–5, increasing through the second week (Maksimov 2017); the cold-exposure regimen used a single dose before exposure.
- Common pitfalls: reading adaptogen marketing as longevity evidence; using it continuously beyond label courses; substituting agricultural crezacin; and delaying care for a worsening infection.
- Regulatory status: an over-the-counter medicine in Russia (registration LP-No(010553)-(RG-RU), issued June 16, 2025) (Vidal label); no marketing authorization or supplement status outside Russia and neighboring markets was identified.
- Cost and access: inexpensive in Russia, about 500–1,200 rubles per pack (RLS pharmacy price listing), but difficult to obtain legally elsewhere.
- Language barrier: nearly all primary studies are in Russian, many in journals without English full text.
Interaction with Foundational Habits
- Sleep: none documented; no study has measured sleep, though the compound is framed as stimulating and adaptogenic. Morning or midday dosing by common practice avoids possible evening stimulation.
- Nutrition: indirect; the label specifies dosing after meals. The lactose excipient matters for lactose-intolerant people; no nutrient depletion has been reported. Rat studies show shifts in energy metabolism (more ATP, less lactate) that have not been tested in human diets.
- Exercise: potentiating claim, mechanism proposed as improved cellular energy supply; cold-stressed men kept physical performance (Zarubina 2008). Whether it helps or blunts training adaptation, strength or muscle growth in healthy, trained adults is untested.
- Stress management: potentiating claim for physical stressors (cold, low oxygen, heat) based on the adaptogen concept; human data cover cold only. Cortisol and psychological stress responses have not been measured in controlled human studies.
Monitoring Protocol & Defining Success
Before a first course, baseline testing establishes a reference for safety and response: a complete blood count with differential, fasting glucose for anyone with diabetes or impaired glucose control, and serum creatinine. Lactose tolerance and any history of drug allergy, autoimmune disease or immunosuppressive treatment are also confirmed, because these define label contraindications or inferred risks.
Ongoing monitoring follows the short course structure: a repeat blood count at the end of each 8–14-day course if baseline values were abnormal, daily home glucose readings during each course for people with diabetes, and creatinine every 6–12 months if courses are repeated several times a year. Success is defined as fewer or shorter respiratory infections and better tolerance of physical stress over several courses compared with the individual’s own baseline, rather than as a change in any aging biomarker, since none has been studied.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| White blood cell count with lymphocyte count | 4.5–11.0 ×10⁹/L total; lymphocytes 1.0–4.8 ×10⁹/L (standard reference range) | Expected change: immune modulation | Non-fasting; repeat at course end; in the infection study, faster normalization of high counts occurred only with baseline leukocytosis above three times normal plus ESR above 20 mm/h (Frolova 2021) |
| ESR (erythrocyte sedimentation rate) | 0–20 mm/h (standard reference range) | Expected change: inflammation marker shown to fall faster | Non-fasting; pair with white-cell count; changes seen only when baseline ESR exceeded 20 mm/h together with marked leukocytosis, although the abstract reports faster ESR, leukocyte and CRP (C-reactive protein, a blood marker of inflammation) normalization overall and the full text found no significant CRP difference (Frolova 2021) |
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Safety check: label caution in diabetes | 8–12-hour fast, morning draw; relevant mainly for people with diabetes (Vidal label) |
| Serum creatinine | 0.7–1.3 mg/dL men; 0.6–1.1 mg/dL women (standard reference range) | Safety check: renal excretion; kidney damage from triethanolamine in rats | No heavy exercise in the 24 hours before; pair with eGFR (estimated glomerular filtration rate, a kidney-filtration estimate); rat data in Maekawa 1986 |
Qualitative markers:
- Number and duration of respiratory infections per season, compared with the individual’s own previous seasons
- Fatigue and energy during heavy physical or mental workloads
- Tolerance of cold, heat or altitude exposure
- Sleep quality during courses
- Any skin rash, itching or swelling, as an allergy warning sign
Emerging Research
- No registered trials: a ClinicalTrials.gov search lists no study of Trekrezan or its synonyms as of October 25, 2026, so there is no NCT ID; no ongoing trial could currently confirm or overturn the infection or performance findings for health-focused adults.
- Placebo-controlled infection trials: the only comparative infection study was open-label with an untreated control (Frolova 2021); a blinded trial could strengthen the case or show a placebo-sized effect.
- Protein-synthesis pathway: developer-group studies link it to tryptophanyl-tRNA synthetase expression (Nurbekov 2011), and a zinc analogue also activates this enzyme (Rasulov 2012); independent replication could confirm or dismiss this pathway.
- Triethanolamine safety: the International Agency for Research on Cancer rated triethanolamine not classifiable as a human carcinogen (IARC Monograph 77); a study by Dow Chemical, a triethanolamine producer, found no meaningful conversion to a nitrosamine carcinogen in mice (Saghir 2005). Oral human data remain absent.
- Longevity testing: no lifespan study in worms, flies or rodents exists; such a study would be the first direct test of longevity relevance, and a null result would leave only short-term stress uses.
- Analogue development: related salts reported to have antitumor activity in experimental models (Voronkov 2002) may displace Trekrezan if further developed.
Conclusion
Trekrezan is a synthetic salt developed in Soviet Siberia, first for farming and then as a Russian over-the-counter medicine meant to raise general resistance to infection, cold, low oxygen and heavy workloads. For health-focused adults looking at it through a longevity lens, the central finding is that it has never been studied for aging, lifespan or long-term health in any species.
The human evidence is thin. One open study without a dummy treatment suggests that colds and similar infections resolve somewhat faster, and one small study in young men suggests that physical performance holds up better in cold conditions. Claims about mental performance, heart function and recovery from alcohol withdrawal rest on weaker reports, and the only controlled test of mental performance found no change. A liver benefit in hepatitis rests on a secondary report, and most other effects, including immune and blood-vessel actions, come from animal and laboratory work.
Short courses appear well tolerated, with allergic reactions listed on the label. The main open safety question concerns long-term exposure to the industrial base that forms one half of the salt, which produced tumors and kidney damage in some animal studies but not others.
The evidence base is small, mostly in Russian, and produced largely by the compound’s developers and their collaborators, which is a clear conflict of interest. For people optimizing long-term health, Trekrezan remains a short-term stress and infection aid with an unknown relationship to longevity.